The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.
Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.
The genomic testing platform developer has now raised some $140m, eight years after being co-founded in EPFL's Innovation Park by researchers from EMBL, Stanford and Geneva University.
Autoimmune disease therapy spinout Cabaletta Bio's series B round brought its total to at least $88m allowed the university to pare back its shareholding.
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Stanford-StartX Fund has returned to pump funding into electric skateboard manufacturer Boosted, helping to take the company’s total funding to $70m.
Immunotherapy spinout Annexon Biosciences collected funding from Novartis Venture Fund in a series C round that brought its total funding to $154m.
MRL Ventures Fund and Roche Fund have taken part in the intracellular drug developer's series A, which is commercialising research by Prof Dehua Pei at OSU.
Synspective has been backed by a University of Tokyo VC vehicle in its bid to launch a constellation of 25 small Earth observation satellites powered by synthetic aperture radar.
Foresite Capital and F-Prime Capital joined earlier series B investors including Oxford Science Innovations to take Oxford drug discovery spinout Genomics’ total funding to $58.2m.